MedTrace Logo

To Explore the Therapeutic Potential of Jiedu Yizhi Formula for Alzheimer 's Disease

NCT06393413 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2024-05-02

No results posted yet for this study

Summary

AD patients who met the inclusion criteria in the encephalopathy clinic and treatment area of the Third Clinical Hospital Affiliated to Changchun University of Traditional Chinese Medicine from December 2022 to December 2023 were collected and randomly divided into traditional Chinese medicine experimental group and western medicine control group. The experimental group was treated with Jiedu Yizhi Formula, and the control group was treated with Donepezil Hydrochloride Tablets ( trade name : Aricept ). The two groups were given AD cognitive behavior training and health education at the same time. The course of treatment was 24 weeks. The Western medicine scale was measured before treatment, 12 weeks after treatment and 24 weeks after treatment to evaluate the effect of drugs on cognitive function and daily living ability.

Conditions

  • Ensure the Legality and Compliance of the Testing Process

Interventions

DRUG

Jiedu Yizhi Formula

Observation after 24 weeks of drug treatment

DRUG

Donepezil Hydrochloride Tablets

Donepezil Hydrochloride Tablets

Sponsors & Collaborators

  • Changchun University of Chinese Medicine

    lead OTHER

Principal Investigators

  • Wei Zhang, Dr. · Affiliated Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
55 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-01
Primary Completion
2023-12-01
Completion
2024-04-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06393413 on ClinicalTrials.gov